Table 3. Cox-proportional hazard model of factors associated with t-MNs.
Variables | Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | ||
Age at OC or PPC | 0.86 | 0.68–1.08 | 0.18 | 0.87 | 0.64–1.18 | 0.37 | |
Presence of other cancer | 0.71 | 0.06–8.21 | 0.79 | ||||
Number of chemotherapy agent | 1.55 | 0.79–3.05 | 0.21 | ||||
PARPi usage period | 0.96 | 0.90–1.02 | 0.18 | 0.96 | 0.89–1.03 | 0.24 | |
OS from OC diagnosis | 1.25 | 0.96–1.64 | 0.10 | 1.35 | 0.85–2.16 | 0.21 |
t-MNs, therapy-related myeloid neoplasms; HR, hazard ratio; CI, confidence interval; OC, ovarian cancer; PPC, primary peritoneal cancer; PARPi, poly(ADP-ribose) polymerase inhibitor; OS, overall survival.